1. Younossi, Z, Anstee, QM, Marietti, M, et al. (2018) Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 15, 11–20.
2. Younossi, ZM, Blissett, D, Blissett, R, et al. (2016) The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology 64, 1577–1586.
3. Hardy, T, Oakley, F, Anstee, QM, et al. (2016) Nonalcoholic fatty liver disease: pathogenesis and disease spectrum. Annu Rev Pathol 11, 451–496.
4. Paschos, P & Paletas, K (2009) Non alcoholic fatty liver disease and metabolic syndrome. Hippokratia 13, 9–19.
5. Marchesini, G, Brizi, M, Morselli-Labate, AM, et al. (1999) Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 107, 450–455.
6. Loomba, R, Abraham, M, Unalp, A, et al. (2012) Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. Hepatology 56, 943–951.
7. Friedman, SL (1999) Stellate cell activation in alcoholic fibrosis – an overview. Alcohol Clin Exp Res 23, 904–910.
8. Parola, M & Robino, G (2001) Oxidative stress-related molecules and liver fibrosis. J Hepatol 35, 297–306.
9. Pellicoro, A, Ramachandran, P, Iredale, JP, et al. (2014) Liver fibrosis and repair: immune regulation of wound healing in a solid organ. Nat Rev Immunol 14, 181–194.
10. Koyama, Y & Brenner, DA (2017) Liver inflammation and fibrosis. J Clin Invest 127, 55–64.
11. Li, L, Duan, M, Chen, W, et al. (2017) The spleen in liver cirrhosis: revisiting an old enemy with novel targets. J Transl Med 15, 111–121.
12. Liu, P, Li, P, He, W, et al. (2009) Liver and spleen volume variations in patients with hepatic fibrosis. World J Gastroenterol 15, 3298–3302.
13. Tarao, K, Hoshino, H, Motohashi, I, et al. (1989) Changes in liver and spleen volume in alcoholic liver fibrosis of man. Hepatology 9, 589–593.
14. Jeong, WK (2017) Hepatic and splenic volumetry could be used as an imaging parameter to evaluate fibrosis grades of the diffuse liver disease including nonalcoholic fatty liver disease. Gut Liver 11, 577–578.
15. Mandal, M, Gardner, CR, Sun, R, et al. (2016) The spleen as an extramedullary source of inflammatory cells responding to acetaminophen-induced liver injury. Toxicol Appl Pharmacol 304, 110–120.
16. Yada, A, Iimuro, Y, Uyama, N, et al. (2015) Splenectomy attenuates murine liver fibrosis with hypersplenism stimulating hepatic accumulation of Ly-6C(lo) macrophages. J Hepatol 63, 905–916.
17. Younossi, ZM (2008) Review article: current management of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther 28, 2–12.
18. Samuels, R, Mani, UV, Iyer, UM, et al. (2002) Hypocholesterolemic effect of spirulina in patients with hyperlipidemic nephrotic syndrome. J Med Food 5, 91–96.
19. Mao, TK, Van de Water, J & Gershwin, ME (2005) Effects of a spirulina-based dietary supplement on cytokine production from allergic rhinitis patients. J Med Food 8, 27–30.
20. Coskun, ZK, Kerem, M, Gurbuz, N, et al. (2011) The study of biochemical and histopathological effects of spirulina in rats with TNBS-induced colitis. Bratisl Lek Listy 112, 235–243.
21. Rasool, M, Sabina, EP & Lavanya, B (2006) Anti-inflammatory effect of Spirulina fusiformis on adjuvant-induced arthritis in mice. Biol Pharm Bull 29, 2483–2487.
22. Ku, CS, Pham, TX, Park, Y, et al. (2013) Edible blue-green algae reduce the production of pro-inflammatory cytokines by inhibiting NF-kappaB pathway in macrophages and splenocytes. Biochim Biophys Acta 1830, 2981–2988.
23. Ku, CS, Kim, B, Pham, TX, et al. (2015) Blue-green algae inhibit the development of atherosclerotic lesions in apolipoprotein E knockout mice. J Med Food 18, 1299–1306.
24. Park, YK, Rasmussen, HE, Ehler, SJ, et al. (2008) Repression of proinflammatory gene expression by lipid extract of Nostoc commune var sphaeroides Kutzing, a blue-green alga, via inhibition of nuclear factor-kappa B in RAW 264.7 macrophages. Nutr Res 28, 83–91.
25. Rasmussen, HE, Blobaum, KR, Park, YK, et al. (2008) Lipid extract of Nostoc commune var. sphaeroides Kutzing, a blue-green alga, inhibits the activation of sterol regulatory element binding proteins in HepG2 cells. J Nutr 138, 476–481.
26. Akahoshi, T, Hashizume, M, Tanoue, K, et al. (2002) Role of the spleen in liver fibrosis in rats may be mediated by transforming growth factor beta-1. J Gastroenterol Hepatol 17, 59–65.
27. Rockey, DC (2006) Hepatic fibrosis, stellate cells, and portal hypertension. Clin Liver Dis 10, 459–479, vii–viii.
28. Bolognesi, M, Merkel, C, Sacerdoti, D, et al. (2002) Role of spleen enlargement in cirrhosis with portal hypertension. Dig Liver Dis 34, 144–150.
29. Leuschner, F, Rauch, PJ, Ueno, T, et al. (2012) Rapid monocyte kinetics in acute myocardial infarction are sustained by extramedullary monocytopoiesis. J Exp Med 209, 123–137.
30. Kim, E, Yang, J, Beltran, CD, et al. (2014) Role of spleen-derived monocytes/macrophages in acute ischemic brain injury. J Cereb Blood Flow Metab 34, 1411–1419.
31. Hsiao, HM, Fernandez, R, Tanaka, S, et al. (2018) Spleen-derived classical monocytes mediate lung ischemia–reperfusion injury through IL-1beta. J Clin Invest 128, 2833–2847.
32. Yang, Y, Park, Y, Cassada, DA, et al. (2011)
In vitro and in vivo safety assessment of edible blue-green algae, Nostoc commune var. sphaeroides Kutzing and Spirulina platensis
. Food Chem Toxicol 49, 1560–1564.
33. Pham, TX, Park, YK, Bae, M, et al. (2017) The potential role of an endotoxin tolerance-like mechanism for the anti-inflammatory effect of Spirulina platensis organic extract in macrophages. J Med Food 20, 201–210.
34. Swirski, FK, Nahrendorf, M, Etzrodt, M, et al. (2009) Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science 325, 612–616.
35. Li, L, Wei, W, Li, Z, et al. (2018) The spleen promotes the secretion of CCL2 and supports an M1 dominant phenotype in hepatic macrophages during liver fibrosis. Cell Physiol Biochem 51, 557–574.
36. Zou, J, Lai, B, Zheng, M, et al. (2017) CD4+ T cells memorize obesity and promote weight regain. Cell Mol Immunol 15, 630–639.
37. Boi, SK, Buchta, CM, Pearson, NA, et al. (2016) Obesity alters immune and metabolic profiles: new insight from obese-resistant mice on high-fat diet. Obesity (Silver Spring) 24, 2140–2149.
38. Ronda, SR & Lele, SS (2008) Culture conditions stimulating high gamma-linolenic acid accumulation by Spirulina platensis
. Braz J Microbiol 39, 693–697.
39. Chang, CS, Sun, HL, Lii, CK, et al. (2010) Gamma-linolenic acid inhibits inflammatory responses by regulating NF-kappaB and AP-1 activation in lipopolysaccharide-induced RAW 264.7 macrophages. Inflammation 33, 46–57.
40. Furse, RK, Rossetti, RG, Seiler, CM, et al. (2002) Oral administration of gammalinolenic acid, an unsaturated fatty acid with anti-inflammatory properties, modulates interleukin-1beta production by human monocytes. J Clin Immunol 22, 83–91.
41. Gonzalez, R, Rodriguez, S, Romay, C, et al. (1999) Anti-inflammatory activity of phycocyanin extract in acetic acid-induced colitis in rats. Pharmacol Res 39, 55–59.
42. Cherng, SC, Cheng, SN, Tarn, A, et al. (2007) Anti-inflammatory activity of c-phycocyanin in lipopolysaccharide-stimulated RAW 264.7 macrophages. Life Sci 81, 1431–1435.
43. Ciccone, MM, Cortese, F, Gesualdo, M, et al. (2013) Dietary intake of carotenoids and their antioxidant and anti-inflammatory effects in cardiovascular care. Mediators Inflamm 2013, 782137.